Mr. Shawn Guse is a co-founder and the President and CEO of Intuitive Biosciences. Mr. Guse previously served as Vice President and General Counsel at TomoTherapy where he led the largest initial public offering in Wisconsin history and also led its licensing and acquisition activities. Mr. Guse started his career in Law serving in private practice for more than 10 years. Mr. Guse received his law degree from the University of Wisconsin in 1995.
Dr. Kimberly Luke joined Intuitive Biosciences in March 2012 and currently serves as Director of Commercial Development. Prior to Intuitive Biosciences, Kim served in various scientific roles for Gentel Biosciences including managing the CSA: Simian product lines and development of new products. Kim has extensive experience in microarray assay development at prior roles in Pfizer (formerly Pharmacia) and Integrated Genomics. Kim received her PhD in 2007 from the University of Wisconsin-Madison with a focus in medical microbiology and immunology.
Dr. John Bart joined Intuitive Biosciences in March 2012 and currently serves as Director of Manufacturing. Prior to joining Intuitive, John worked for Gentel Biosciences with roles as Senior Scientist and later as Manufacturing Manager. Previously John worked for eight years at ThermoElectron as a Senior Scientist. John has nearly two decades of industrial and government experience doing product development, production and QA/QC in the areas of protein microarray, medical diagnostics and immunosensors. John received his PhD in Chemistry from Caltech in 1994.